Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| PRAXPraxis Precision Medicines I | $14.4M | 10.5% | |
| WHWKWhitehawk Therapeutics Inc | $9.9M | 7.3% | |
| ERASErasca Inc | $8.3M | 6.1% | +33.8% |
| TRVITrevi Therapeutics Inc | $7.7M | 5.7% | |
| STROSutro Biopharma Inc | $7.5M | 5.5% | |
| TNGXTango Therapeutics Inc | $7.2M | 5.3% | |
| MBXMbx Biosciences Inc | $6.7M | 4.9% | |
| PTGXProtagonist Therapeutics Inc | $6.5M | 4.8% | |
| EWTXEdgewise Therapeutics Inc | $5.4M | 4.0% | |
| TNDMTandem Diabetes Care Inc | $4.5M | 3.3% | New |
| IRONDisc Medicine Inc | $4.3M | 3.1% | |
| SVRASavara Inc | $3.7M | 2.7% | |
| AVBPArrivent Biopharma Inc | $3.5M | 2.6% | New |
| INSMInsmed Inc | $3.0M | 2.2% | |
| ACHVAchieve Life Sciences Inc | $3.0M | 2.2% | |
| IDYAIdeaya Biosciences Inc | $3.0M | 2.2% | |
| OCULOcular Therapeutix Inc | $2.9M | 2.2% | |
| AXSMAxsome Therapeutics Inc. | $2.9M | 2.2% | −66.9% |
| DSGNDesign Therapeutics Inc | $2.7M | 2.0% | New |
| UTHRUnited Therapeutics Corp Del | $2.6M | 1.9% | |
| SRRKScholar Rock Hldg Corp | $2.5M | 1.8% | |
| IMMXImmix Biopharma Inc | $2.4M | 1.7% | |
| VRDNViridian Therapeutics Inc | $2.3M | 1.7% | |
| MLYSMineralys Therapeutics Inc | $2.3M | 1.7% | New |
| DRUGBright Minds Biosciences Inc | $2.2M | 1.6% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| IMMXImmix Biopharma Inc | December 31, 2025 | +97.1% | $2.4M |
| WHWKWhitehawk Therapeutics Inc | December 31, 2025 | +89.3% | $9.9M |
| MBXMbx Biosciences Inc | December 31, 2025 | +75.0% | $6.7M |
| NKTRNektar Therapeutics | December 31, 2025 | +65.1% | $1.9M |
| EWTXEdgewise Therapeutics Inc | December 31, 2025 | +63.7% | $5.4M |
| TNGXTango Therapeutics Inc | March 31, 2026 | +49.4% | $7.2M |
| TRVITrevi Therapeutics Inc | December 31, 2025 | +49.0% | $7.7M |
| TVTXTravere Therapeutics Inc | December 31, 2025 | +48.7% | $2.2M |
| CABACabaletta Bio Inc | December 31, 2025 | +42.0% | $1.6M |
| PTGXProtagonist Therapeutics Inc | December 31, 2025 | +40.3% | $6.5M |
Sold off last quarter
- Terns Pharmaceuticals IncCUSIP 880881107 was $23.2M
- RVMDRevolution Medicines Inc was $3.9M
- Soleno Therapeutics IncCUSIP 834203309 was $2.0M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +19.2% | +14.8% |
| March 31, 2026 | +9.0% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: KVP Capital Advisors, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1858198&type=13F-HR&dateb=&owner=include&count=40CIK 1858198
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1858198/000110465926095988/Filed August 13, 2026 · accession 0001104659-26-095988